FRANKLIN, Tenn. / Aug 27, 2025 / Business Wire / Community Health Systems, Inc. (NYSE:CYH) today announced that management will participate in the 2025 Wells Fargo Healthcare Conference to be held September 3-5, 2025.
The fireside chat presentation will begin at 11:00 a.m. Eastern time, 10:00 a.m. Central time, on Wednesday, September 3, 2025, and will be available to investors via a live audio webcast. A link to the broadcast can be found at the investor relations section of the Company’s website, www.chs.net, and a replay will be available using that same link.
About Community Health Systems, Inc.
Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 36 distinct markets across 14 states. The Company’s subsidiaries own or lease 70 affiliated hospitals with more than 10,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.
Last Trade: | US$2.76 |
Daily Change: | -0.04 -1.43 |
Daily Volume: | 843,450 |
Market Cap: | US$386.730M |
July 22, 2025 February 18, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load